Drug Trial Radar · NCT07700160
First-in-Human Trial of VBC108 in Participants With Advanced Malignant Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
230
Planned (sponsor's estimate)
Start
Jul 30, 2026
Primary completion
Jul 7, 2029
Study completion Sep 17, 2029
Sponsor
- Lead sponsor
- VelaVigo Bio IncIndustry
- Sponsor type
- Industry
- First posted
- Jul 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open-label, multiple-dose, FIH Phase 1/2a trial. The Phase 1 portion uses Bayesian optimal interval (BOIN) design to escalate and determine the MTD and/or RP2D with potential backfill cohorts. The Phase 2a portion consists of dose optimization followed by cohort expansion to confirm safety and tolerability and to further evaluate the efficacy of the selected RP2D in selected solid tumor malignancies for VBC108.
Conditions
- Advanced Solid Tumors
Interventions
VBC108Drug
VBC108
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of dose-limiting toxicities (DLT) as defined in the protocolTime frame: From time of first dose of VBC108 to end of DLT period ( 21 days)
- Incidence of Serious Adverse EventsTime frame: From time of Informed Consent to 30 days post last dose of VBC108
- Incidence of Adverse Events (AEs)Time frame: From time of Informed Consent to 30 days post last dose of VBC108
- Objective Response Rate (ORR)Time frame: From first dose of VBC108 to disease progression or death, up to approximately 2 years
Locations
12 sites in 3 countries. Site status is shown where the registry gives one.
City of Hope Medical Center
Duarte, California · Recruiting
START Midwest, LLC
Grand Rapids, Michigan · Recruiting
Laura and Issac Perlmutter Cancer Center
New York, New York · Not yet recruiting
Next Oncology - Oncology
San Antonio, Texas · Recruiting
NEXT Oncology Virginia
Fairfax, Virginia · Recruiting
GenesisCare North Shore
St Leonards, New South Wales, Australia · Recruiting
One Clinical Research
Perth, Western Australia, Australia · Not yet recruiting
Beijing Cancer Hospital
Beijing, Beijing Municipality, China · Not yet recruiting
Beijing GoBroad Hospital
Beijing, Beijing Municipality, China · Not yet recruiting
Zhongshan Hospital
Shanghai, Shanghai Municipality, China · Not yet recruiting
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Not yet recruiting
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.